Integra LifeSciences Holdings Corporation IART
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 411.18M | 418.76M | 391.92M | 434.93M | 402.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 411.18M | 418.76M | 391.92M | 434.93M | 402.06M |
| Cost of Revenue | 182.97M | 185.09M | 163.50M | 189.79M | 172.23M |
| Gross Profit | 228.21M | 233.67M | 228.42M | 245.13M | 229.84M |
| SG&A Expenses | 162.02M | 167.22M | 165.16M | 334.64M | 167.34M |
| Depreciation & Amortization | 3.76M | 3.77M | 3.78M | 3.77M | 3.73M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 369.53M | 378.47M | 351.13M | 760.44M | 362.57M |
| Operating Income | 41.65M | 40.29M | 40.79M | 109.41M | 39.49M |
| Income Before Tax | 15.66M | 4.74M | -2.41M | 4.31M | -6.82M |
| Income Tax Expenses | 812.00K | 262.00K | 2.21M | 6.01M | -1.42M |
| Earnings from Continuing Operations | 14.85M | 4.48M | -4.62M | -1.70M | -5.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.85M | 4.48M | -4.62M | -1.70M | -5.40M |
| EBIT | 41.65M | 40.29M | 40.79M | 109.41M | 39.49M |
| EBITDA | 80.71M | 78.43M | 79.22M | 186.27M | 78.01M |
| EPS Basic | 0.19 | 0.06 | -0.06 | -0.02 | -0.07 |
| Normalized Basic EPS | 0.25 | 0.22 | 0.23 | 0.28 | 0.18 |
| EPS Diluted | 0.19 | 0.06 | -0.06 | -0.02 | -0.07 |
| Normalized Diluted EPS | 0.24 | 0.22 | 0.23 | 0.28 | 0.18 |
| Average Basic Shares Outstanding | 77.39M | 77.29M | 76.95M | 76.78M | 76.75M |
| Average Diluted Shares Outstanding | 78.58M | 78.17M | 76.95M | 76.78M | 76.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |